B+
Bull case
25%
Probability
Target price
$145.00
+1.8% vs current
ICUI
ICU MedicalCNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-16
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$118.00
-17.1% vs current
B-
Bear case
30%
Probability
Target price
$102.00
-28.4% vs current
AI sentiment snapshot
Latest data as of 2026-05-09
Recent news sentiment (30D)
-30.2
Negative
Company
-
Unavailable
Macro
-30.2
Negative
Pulse
-
Unavailable
Sentiment proxy
+31.8
Score
AI commentary
As of May 9, 2026, the near-term tone is mixed-to-cautious: the company delivered a modest earnings beat on May 7, 2026, and checked market coverage showed a positive same-day reaction of about 2.9%, but the move was not large enough to prove a thesis reset, and delayed analyst revision evidence remained thin in checked sources. With strong primary filing context but only moderate forward catalyst density and a negative deterministic prior, this still reads more like a post-earnings monitoring setup than a high-conviction bullish inflection.
RankAlpha Sentiment Codex - 2026-05-09
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-15catalystQ1 earnings beat produced only a modest initial reratingMedium impact
On May 7, 2026, ICU Medical reported Q1 revenue of $530.2 million, adjusted EPS of $1.97, GAAP gross margin of 39%, and said results were generally in line with expectations; AP/Zacks-reported consensus cited in checked coverage was $519.9 million revenue and $1.78 adjusted EPS, while MarketScreener showed the stock closed at $123.07, up 2.91% that day, implying the beat did not fully change the narrative yet [#8-K-2026-05-07].
2026-08-06catalystCore Consumables and Infusion Systems growth can offset divestiture noise if sustainedHigh impact
Q1 2026 Consumables revenue rose to $278.3 million and Infusion Systems revenue rose to $179.6 million; the 10-Q says Consumables growth was driven primarily by new customer installations and increased demand for Infusion Consumables and Oncology, while the press release said organic revenue increased 1% excluding the IV Solutions divestiture and FX [#10-Q-2026-05-07] [#8-K-2026-05-07].
2026-12-31eventFDA pump remediation and 510(k) resubmission remain unresolved overhangsHigh impact
The March 31, 2026 10-Q says ICU Medical withdrew 510(k) applications for next-generation MedFusion and updated CADD pumps after FDA requests for additional testing and is planning to resubmit as soon as possible; until the 2025 warning-letter matters are resolved to FDA satisfaction, the company says additional legal or regulatory action may occur and no loss contingency is recorded because the impact cannot yet be predicted [#10-Q-2026-05-07].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-09 • Updated nightlySource: Internal modelMethodology